Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VS-7375
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Verastem Oncology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Verastem Exercises Option for VS-7375, Updates KRAS G12D Phase 1 Data
Details : Under the license agreement terms for VS-7375 (GFH375), Verastem receives an exclusive global license to VS-7375 outside of the GenFleet markets of mainland China.
Product Name : VS-7375
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 14, 2025
Lead Product(s) : VS-7375
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Verastem Oncology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : SLS009
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GenFleet Receives FDA Fast Track and Orphan Drug Designations for GFH009
Details : SLS009 (GFH009) is a selective CDK9 inhibitor showing anti-tumor activity, investigated for relapsed/refractory peripheral T-cell lymphomas and acute myeloid leukemia.
Product Name : GFH009
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2024
Lead Product(s) : SLS009
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fulzerasib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GenFleet Announces KRAS G12C Inhibitor Approval in China for Lung Cancer
Details : Dupert (fulzerasib) is a novel small molecule KRAS G12C inhibitor, which is indicated for the treatment of patients with advanced solid tumors with KRAS G12C mutations.
Product Name : Dupert
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 23, 2024
Lead Product(s) : Fulzerasib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VS-7375
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GenFleet's GFH375 IND Approved in China for KRAS G12D Tumors
Details : KRAS G12D oral selective small molecule inhibitor, GFH375 (VS-7375), is being investigated in patients with KRASG12D mutations, specifically in brain.
Product Name : GFH375
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 19, 2024
Lead Product(s) : VS-7375
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GenFleet Announces FDA Approval for GFH925 Monotherapy in Phase 3 Colorectal Cancer Study
Details : GFH925 (IBI351) is a novel small molecule KRAS G12C inhibitor, which is being evaluated for the treatment of patients with colorectal cancer with KRAS G12C mutations.
Product Name : GFH925
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2024
Lead Product(s) : GFH925
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GFH925 (IBI351) is a novel small molecule KRAS G12C inhibitor, which is being evaluated for the treatment of patients with advanced solid tumors with KRAS G12C mutations.
Product Name : GFH925
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 24, 2023
Lead Product(s) : GFH925
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SLS009
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of relapsed/refractory PTCL (peripheral T-cell lymphomas).
Product Name : GFH009
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : SLS009
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GFH925,Cetuximab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GFH925 inhibits the GTP/GDP exchange, an essential step in pathway activation. Subsequently, GFH925 inhibits the downstream signal pathway to induce tumor cells' apoptosis and cell cycle arrest. Being developed for advanced NSCLC patients harboring KRASG...
Product Name : GFH925
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2023
Lead Product(s) : GFH925,Cetuximab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GFH925,Cetuximab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : By covalently and irreversibly modifying the cysteine residue of KRAS G12C protein, GFH925 inhibits the GTP/GDP exchange, an essential step in pathway activation.
Product Name : GFH925
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 19, 2022
Lead Product(s) : GFH925,Cetuximab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : GFH312
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GenFleet Receives FDA Approval for Phase II Study of RIPK1 Inhibitor (GFH312)
Details : Preclinical data demonstrated GFH312 is able to inhibit RIPK1 kinase activity in human cells, down-regulate RIPK1 phosphorylation in animal models and curb the inflammatory response of animals' nervous system.
Product Name : GFH312
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2022
Lead Product(s) : GFH312
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable